Nash, P., McInnes, I. B., Mease, P. J., Thom, H., Hunger, M., Karabis, A., . . . Jugl, S. M. (2018). Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison. Rheumatol Ther.
Citação norma ChicagoNash, Peter, Iain B. McInnes, Philip J. Mease, Howard Thom, Matthias Hunger, Andreas Karabis, Kunal Gandhi, Shephard Mpofu, and Steffen M. Jugl. "Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness Up to 48 Weeks Using a Matching-Adjusted Indirect Comparison." Rheumatol Ther 2018.
Citação norma MLANash, Peter, et al. "Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness Up to 48 Weeks Using a Matching-Adjusted Indirect Comparison." Rheumatol Ther 2018.